Evidence map›Paper›PMID 21445962›Full record

ArticleArthritis and rheumatism2011

Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.

Karen H Costenbader, Amrita Desai, Graciela S Alarcón, Linda T Hiraki, Tamara Shaykevich, M Alan Brookhart, Elena Massarotti, Bing Lu, Daniel H Solomon, Wolfgang C Winkelmayer

Registry-linked trialAbstract read
In one paragraph

Article in Arthritis and rheumatism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03492255 (CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid), which is not on this map. Cited by 112 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03492255 naterminatednot on this mapstarted 2018, after this paper: background citation

CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid

TypeinterventionalSponsorUniversity of Sao Paulo General HospitalRan2018 to 2021Enrolled49ConditionsSystemic Lupus Erythematosus (SLE)ArmsCyclophosphamide, Methylprednisolone, Prednisone, Mycophenolate Mofetil
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Immunosuppressive treatment for proliferative lupus nephritis.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Observational
  9. Review
  10. The utility of CXCL13 and circulating CXCR5Frontiers in immunology · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Review

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Karen H CostenbaderBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. Kcostenbader@Partners.org
Amrita Desai
Graciela S Alarcón
Linda T Hiraki
Tamara Shaykevich
M Alan Brookhart
Elena Massarotti
Bing Lu
Daniel H Solomon
Wolfgang C Winkelmayer

Funding

Sociodemographic Disparities in SLE Incidence: Behavioral and Psychosocial FactorsR01AR057327 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2009 to 2019
$6.2M
Patient Centered Outcomes Research in RheumatologyK24AR055989 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SOLOMON, DANIEL HAL · 2008 to 2017
$1.5M
Hierarchical models of prescription drug use in the elderlyK25AG027400 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BROOKHART, MAURICE ALAN · 2006 to 2010
$653k
NIAMS NIH HHS K24 AR055989NIAMS NIH HHS K24-AR-055989NIAMS NIH HHS R01 AR057327NIAMS NIH HHS R01-AR-057327NIA NIH HHS AG-027400NIA NIH HHS K25 AG027400
6 · The paper itself

Abstract

objectiveThis study was undertaken to investigate whether recent advances in lupus nephritis treatment have led to changes in the incidence of end-stage renal disease (ESRD) secondary to lupus nephritis, or in the characteristics, treatments, and outcomes of patients with lupus nephritis ESRD.

methodsPatients with incident lupus nephritis ESRD (1995-2006) were identified in the US Renal Data System. Trends in sociodemographic and clinical characteristics were assessed. We tested for temporal changes in standardized incidence rates (SIRs) for sociodemographic groups using Poisson regression. Changes in rates of waitlisting for kidney transplant, kidney transplantation, and all-cause mortality were examined using crude and adjusted time-to-event analyses.

resultsWe identified 12,344 incident cases of lupus nephritis ESRD. Mean age at ESRD onset was 41 years; 81.6% of the patients were women and 49.5% were African American. SIRs for lupus nephritis ESRD among those who were ages 5-39 years, African American, or lived in the southeastern US increased significantly from 1995 to 2006. Increases in body mass index and in the prevalence of both diabetes mellitus and hypertension were detected. Mean serum hemoglobin level at ESRD onset increased, while that of serum creatinine decreased over time. More patients received hemodialysis and fewer received peritoneal dialysis. There was a slight increase in the frequency of preemptive kidney transplantation at ESRD onset, but kidney transplantation rates within the first 3 years of ESRD declined. Mortality did not change over the 12 years of study.

conclusionOur findings indicate that the characteristics of patients with lupus nephritis ESRD and initial therapies have changed in recent years. While SIRs rose in younger patients, among African Americans, and in the South, outcomes did not improve in over a decade of evaluation.

Indexed as

AdolescentAdultBlack or African AmericanBlack PeopleBody Mass IndexChildChild, PreschoolComorbidityDiabetes MellitusFemaleHumansHypertensionIncidenceKidney Failure, ChronicKidney TransplantationLupus Nephritis

Identifiers

PMID21445962
PMCPMC3106117

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.